BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30377936)

  • 21. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kitajima K; Fukushima K; Yamamoto S; Kato T; Odawara S; Takaki H; Kobayashi K; Yamano T; Yamakado K; Nakanishi Y; Kanematsu A; Nojima M; Suzumura K; Hatano E; Fujimoto J; Kihara T; Nakasho K; Hirota S; Hirota S
    Nagoya J Med Sci; 2017 Feb; 79(2):273-277. PubMed ID: 28626263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
    Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
    Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. F-18 FDG PET in detecting renal cell carcinoma.
    Ak I; Can C
    Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
    Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
    Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lesion detection by [
    Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal Mucinous Tubular and Spindle Cell Carcinoma Shows a High Uptake on
    Furuya S; Manabe O; Nanbu T; Yamashita N; Shinnno Y; Kasai K; Kroenke M; Tamaki N
    Intern Med; 2018 Apr; 57(8):1131-1134. PubMed ID: 29279490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
    Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
    J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.
    Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS
    AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma.
    Ho CL; Chen S; Ho KM; Chan WK; Leung YL; Cheng KC; Wong KN; Cheung MK; Wong KK
    Clin Nucl Med; 2012 Nov; 37(11):1075-82. PubMed ID: 22996247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT.
    Kim JK; Park SY; Shon JH; Cho KS
    Radiology; 2004 Mar; 230(3):677-84. PubMed ID: 14990834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.
    Mizuno T; Kamai T; Abe H; Sakamoto S; Kitajima K; Nishihara D; Yuki H; Kambara T; Betsunoh H; Yashi M; Fukabori Y; Kaji Y; Yoshida K
    BMC Cancer; 2015; 15():1097. PubMed ID: 25784113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.
    Yin Q; Xu H; Zhong Y; Ni J; Hu S
    BMC Cancer; 2022 Feb; 22(1):163. PubMed ID: 35148700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography.
    Ishikawa I; Morita K; Hayama S; Nakazawa T; Araki I; Higashi K; Miyazawa K; Suzuki K; Nojima T
    Clin Exp Nephrol; 2011 Feb; 15(1):136-40. PubMed ID: 20824295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.